Stay updated on Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page now shows Revision: v3.6.6, replacing the previous v3.6.5, indicating a minor administrative update to the study record.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedAdded access to the Study Protocol and Statistical Analysis Plan PDFs in the Study Documents section, along with associated metadata such as file size and upload dates.SummaryDifference72%

- Check45 days agoChange DetectedThe page now shows an updated Revision tag (v3.6.4), replacing the prior revision (v3.6.3) in the page metadata.SummaryDifference0.0%

- Check67 days agoChange DetectedA new revision tag 'Revision: v3.6.3' was added, replacing the previous 'Revision: v3.6.0' tag to indicate an updated patch version on the page.SummaryDifference0.0%

- Check81 days agoChange DetectedNew guidance sections were added to help readers read the study record and understand how to join. The recruitment status was updated to No longer looking for participants, indicating enrollment has closed.SummaryDifference0.3%

- Check88 days agoChange DetectedRevision tag for the study documents updated from v3.5.4 to v3.5.5. This reflects an updated version of the documents referenced on the page.SummaryDifference0.0%

Stay in the know with updates to Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.